ICOS LeukArrest
Executive Summary
Phase II trial of LeukArrest (Hu23F2G) for use following myocardial infarction did not show statistically significant reduction in cardiac damage, as assessed by reduction in infarct size. A Phase II/III trial of the product in ischemic stroke is ongoing, with completion expected in fourth quarter 2000